-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G/AGWOh5rSElFmNeqPaG1ZDzG/bkWOGt69b8fNJ6BHU1yKkKzHItfxelmi983n3d NtyKxL9EnlSqpLyqCgmhAQ== 0000950005-04-000899.txt : 20041230 0000950005-04-000899.hdr.sgml : 20041230 20041230124555 ACCESSION NUMBER: 0000950005-04-000899 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20041230 DATE AS OF CHANGE: 20041230 GROUP MEMBERS: ALIX MARDUEL GROUP MEMBERS: ALTA BIOPHARMA MANAGEMENT, LLC GROUP MEMBERS: ALTA BIOPHARMA PARTNERS, L.P. GROUP MEMBERS: ALTA EMBARCADERO BIOPHARMA PARTNERS, L.P. GROUP MEMBERS: ALTA PARTNERS GROUP MEMBERS: ALTA/CHASE BIOPHARMA MANAGEMENT, LLC GROUP MEMBERS: DANIEL JANNEY GROUP MEMBERS: GARRETT GRUENER GROUP MEMBERS: GUY NOHRA GROUP MEMBERS: JEAN DELEAGE GROUP MEMBERS: LA JOLLA CHASE PARTNERS (ALTA BIO), LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-44849 FILM NUMBER: 041233206 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALTA PARTNERS CENTRAL INDEX KEY: 0001060013 IRS NUMBER: 943238854 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE EMBARCADERO CENTER STREET 2: STE 4050 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 4153624022 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER STREET 2: STE 4050 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 SC 13D/A 1 p19057_13d.txt AMENDMENT #4 EXIT FILING SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 4 Under the Securities Exchange Act of 1934 La Jolla Pharmaceutical Company ------------------------------- (Name of Issuer) Common Stock ------------------------------ (Title of Class of Securities) 503459109 -------------- (CUSIP Number) Hilary Strain One Embarcadero Center, Suite 4050 San Francisco, CA 94111 (415) 362-4022 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 29, 2004 ----------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ] Check the following box if a fee is being paid with this statement: (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class. (See Rule 13d-7). Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act. (Continued on following page(s)) Page 1 of 16 Pages
CUSIP NO. 503459109 13 D 2 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alta Partners - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION California - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IA - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 3 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alta BioPharma Partners, L.P. - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* PN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 4 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alta Embarcadero BioPharma Partners, LLC - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION California - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 5 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) La Jolla Chase Partners (Alta Bio), LLC - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Deleware - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 6 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alta BioPharma Management, LLC - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Deleware - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 7 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alta/Chase BioPharma Management, LLC - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* WC - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Deleware - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 8 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Jean Deleage - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* AF - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 9 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Garrett Gruener - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* AF - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 10 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Daniel Janney - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* AF - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 11 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Alix Marduel - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* AF - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 12 of 16 Pages - ------------------------- ---------------------------------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Guy Nohra - ------------------------- ---------------------------------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------- ---------------------------------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------- ---------------------------------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* AF - ------------------------- ---------------------------------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. - ------------------------- ---------------------------------------------------------------------------------------------------------- EXIT FILING NUMBER OF (7) SOLE VOTING POWER 0 SHARES BENEFICIALLY ---------------------------------------------------------------------------------------------------------- OWNED BY (8) SHARED VOTING POWER 2,826,451 EACH REPORTING PERSON ---------------------------------------------------------------------------------------------------------- WITH (9) SOLE DISPOSITIVE POWER 0 ---------------------------------------------------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 2,826,451 - ------------------------- ---------------------------------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,826,451 EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------- ---------------------------------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6% EXIT FILING - ------------------------- ---------------------------------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------- ---------------------------------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1. Security and Issuer. This Statement on Schedule D relates to the Common Stock, $0.001 par value per share (the "Shares"), of La Jolla Pharmaceutical Company, a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 6455 Nancy Ridge Drive, San Diego, California 92121. EXIT FILING --- The outstanding shares of La Jolla Pharmaceutical Company increased to 61,400,323, resulting in the shares held by the funds affiliated with Alta Partners to drop to 4.6% ownership. See Item 5 (a) Item 2. Identity and Background. (a) This Exit Filing is filed by Alta BioPharma Partners, L.P., a Delaware limited partnership ("Alta BioPharma"), and Alta Embarcadero BioPharma Partners, LLC, a California limited liability company ("Embarcadero LLC"), and La Jolla Chase Partners (Alta Bio), LLC, a Delaware LLC ("La Jolla Alta Bio") by virtue of their direct beneficial ownership of Shares, by Alta BioPharma Management, LLC, a Delaware limited liability company ("Alta Management"), by virtue of being the sole general partner of Alta BioPharma, by Alta/Chase BioPharma Management LLC, a Delaware limited liability company (Alta/Chase Management) by virtue of being the sole managing director of La Jolla Chase Partners (Alta Bio), LLC and by Alta Partners, a California corporation ("Alta Partners"), by virtue of being the management advisory company of these entities. Alta BioPharma, Embarcadero LLC, La Jolla Alta Bio, Alta Management, Alta/Chase Management and Alta Partners are collectively referred to as the "Reporting Persons." Jean Deleage, Garrett Gruener, Dan Janney, Alix Marduel, and Guy Nohra (the "Partners") are the managing directors of Alta Management, Alta/Chase Management and officers of Alta Partners. By virtue of the relationships described above and their roles with Alta Partners, each of the Partners may be deemed to control Alta Partners, Alta/Chase Management, Alta Management, and, therefore, may be deemed to possess indirect beneficial ownership of the Shares held by each entity. However, none of the Partners, acting alone, has voting or investment power with respect to the Shares directly beneficially held by the entities and, as a result, the Partners disclaim beneficial ownership of the Shares directly beneficially owned by each entity, except to the extent of their pecuniary interest in each entity. Embarcadero LLC is a side company that makes all investments pro rata to the capital of Alta BioPharma with all allocations made to its members based on paid-in capital. Certain of the Partners are members of Embarcadero LLC and certain members of Embarcadero LLC are affiliates of Alta Partners. (b) The principal executive offices of Alta BioPharma, Embarcadero LLC, La Jolla Alta Bio, Alta Management, Alta/Chase Management and Alta Partners, and the business address of each Partner, are located at One Embarcadero Center, Suite 4050, San Francisco, California 94111. (c) Alta Partners provides investment advisory services to several venture capital funds. Alta BioPharma, La Jolla Alta Bio and Embarcadero LLC's principal business is acting as venture capital investment vehicles. Alta/Chase Management and Alta Management's principal business is acting as managing director of La Jolla Alta Bio and Alta BioPharma, respectively. Each of the Partners' principal business is acting as a managing director of Alta Management and Alta/Chase Management and as an officer of Alta Partners. (d) None of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the Partners, has been convicted in a criminal proceeding in the past five years (excluding traffic violations or similar misdemeanors). 13 of 16 Pages (e) During the past five years, none of the Reporting Persons or, to the knowledge of the Reporting Persons, none of the Partners, was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws of finding any violation with respect to such laws. (f) Alta Partners is a California corporation. Alta BioPharma is a Delaware limited partnership. Embarcadero LLC is a California limited liability corporation. La Jolla Alta Bio is a Delaware limited liability company. Alta Management and Alta/Chase Management are Delaware limited liability companies. Each of the Partners is a citizen of the United States. Item 3. Source and Amount of Funds or Other Consideration. N/A Exit Filing The outstanding shares of La Jolla Pharmaceutical Company increased to 61,400,323, resulting in the shares held by the funds affiliated with Alta Partners to drop to 4.6% ownership. See Item 5 (a). Item 4. Purpose of Transaction. Exit Filing ---- See Item 5 (a) Item 5. Interest in Securities of the Issuer. Exit Filing ------ The funds affiliated with Alta Partners beneficially own 2,826,451 shares or approximately 4.6% of the shares deemed outstanding by the Company (61,400,323) as of November 30, 2004. Alta BioPharma is the direct beneficial owner of 1,756,883 shares of Common Stock or approximately 2.86% of the shares deemed outstanding by the Company (61,400,323) as of November 30, 2004. La Jolla Alta Bio is the direct beneficial owner of 1,003,348 shares of Common Stock or approximately 1.63% of the shares deemed outstanding by the Company (61,400,323) as of November 30, 2004. Embarcadero LLC is the direct beneficial owner of 66,220 shares of Common Stock or approximately 0.11% of the shares deemed outstanding by the Company (61,400,323) as of November 30, 2004 Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Exit Filing Item 7. Material to be Filed as Exhibits. None 14 of 16 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 29, 2004 Alta Partners Alta BioPharma Partners, L.P. By: /s/ Jean Deleage By: Alta BioPharma Management, LLC - -------------------- Its General Partner Jean Deleage, Vice President Alta BioPharma Management, LLC By: /s/ Daniel Janney --------------------- Daniel Janney, Managing Director By: /s/ Jean Deleage La Jolla Chase Partners (Alta Bio), LLC - -------------------- Jean Deleage, Member By: Alta/Chase BioPharma Management, LLC Alta/Chase BioPharma Management, LLC Its Managing Member By: /s/ Daniel Janney By: /s/ Daniel Janney - --------------------- --------------------- Daniel Janney, Member Daniel Janney, Member Alta Embarcadero BioPharma Partners, LLC By: /s/ Jean Deleage - -------------------- Jean Deleage, Member /s/ Jean Deleage /s/ Guy Nohra - ---------------- ------------- Jean Deleage Guy Nohra /s/ Garrett Gruener /s/ Alix Marduel - ------------------- ---------------- Garrett Gruener Alix Marduel /s/ Daniel Janney - ----------------- Daniel Janney 15 of 16 Pages EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us. Date: December 29, 2004 Alta Partners Alta BioPharma Partners, L.P. By: /s/ Jean Deleage By: Alta BioPharma Management, LLC - -------------------- Its General Partner Jean Deleage, Vice President Alta BioPharma Management, LLC By: /s/ Daniel Janney --------------------- Daniel Janney, Managing Director By: /s/ Jean Deleage La Jolla Chase Partners (Alta Bio), LLC - -------------------- Jean Deleage, Member By: Alta/Chase BioPharma Management, LLC Alta/Chase BioPharma Management, LLC Its Managing Member By: /s/ Daniel Janney By: /s/ Daniel Janney - --------------------- --------------------- Daniel Janney, Member Daniel Janney, Member Alta Embarcadero BioPharma Partners, LLC By: /s/ Jean Deleage - -------------------- Jean Deleage, Member /s/ Jean Deleage /s/ Guy Nohra - ---------------- ------------- Jean Deleage Guy Nohra /s/ Garrett Gruener /s/ Alix Marduel - ------------------- ---------------- Garrett Gruener Alix Marduel /s/ Daniel Janney - ----------------- Daniel Janney 16 of 16 Pages -----END PRIVACY-ENHANCED MESSAGE-----